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population-based MS survey for relapse rates. A network meta-analysis was con-
ducted to estimate the comparative efficacy of each treatment versus placebo. 
Costs (in 2013 Euro) of drug acquisition, disease management, relapses, and AEs 
were from public databases and literature. Clinical and economic outcomes were 
projected over 30 years and discounted at 3.5% per year. Results: Over 30 years, 
treatment with PEG-IFN resulted in higher QALYs and cost-savings compared 
with all commercially available self-injectable DMTs in Ireland. Deterministic 
sensitivity analyses confirmed the results were robust. Probabilistic sensitivity 
analyses indicated that the incremental cost-effectiveness ratio was below the 
willingness-to-pay threshold (€ 45,000 per QALY) in > 85% of 5,000 replications 
versus all comparators. ConClusions: PEG-IFN is a cost-effective treatment for 
patients with RRMS in Ireland.
PND46
Cost-EffECtivENEss ANAlysis of GlybErA for thE trEAtmENt of 
liPoProtEiN liPAsE DEfiCiENCy
Han X, Ni W
University of Southern California, Los Angeles, CA, USA
objeCtives: Glybera is the first gene therapy drug for lipoprotein lipase deficiency 
(LPLD), which was approved by European Commission in 2012. Before the approval 
of Glybera, no effective treatment was available for LPLD. Patients with LPLD have 
to restrictively control fat intaken and are still more likely to suffer recurrent acute 
pancreatitis and eruptive xanthomas. Although Glybera can effectively improve 
the health conditoin of patients with LPLD, it is still controversial to price the 
gene therapy at 1.1 million euros. This study assesses the relative costs and effec-
tiveness of Glybera compared to no treatment for LPLD from a societal perspec-
tive. Methods: We developed a Markov model that tracked a cohort of patients 
through the three disease states of LPLD progression, defined by the symptoms of 
pancreatitis. We evaluated the effectiveness of the noval gene therapy based on pub-
lished clinical trial data. We derived quality of life utility scores and costs data for 
each disease state from the published literature. We estimated the discounted costs, 
quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs). 
Univariate sensitivity analyses were conducted to assess the impact of param-
eter uncertainty on our results. Results: The incremental cost-effective ratio 
(ICER) of Glybera was € 51,789/QALY gained when compared with no intervention. 
Correspondingly, the net monetary benefit (NMB) is € 667,478, given the willingness-
to-pay (WTP) is € 114,875. One-way sensitivity analyses were performed to investi-
gate the model robustness. The analyses illustrated that the model was robust to 
the majority transition probabilities and utility of each health state. ConClusions: 
Although the price is high, Glybera is a cost-effective treatment for lipoprotein 
lipase deficiency compared with no treatment based on available clinical data. This 
conclusion is robust to sensitivity analyses.
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objeCtives: To assess the cost-effectiveness of EGb761® for the treatment of 
mild dementia due to Alzheimer’s disease (AD) and vascular dementia (VaD) 
in the Czech Republic in comparison to no treatment or acetylcholinesterase 
inhibitor (AChEI-donepezil; only AD). Methods: Developed ten-year Markov 
cohort model with half-year cycle length projects outcomes (Quality-Adjusted 
Life-Years-QALYs; Life-Years Gained-LYGs) and costs of treatment for patients 
with AD and VaD aged 65 years from payers’ perspective. Model health states are 
defined by the severity of dementia according to Mini-Mental State Examination 
(MMSE), i.e. no&minimal/mild/moderate/moderately severe/severe dementia and 
by death. Treatment schemes of dementia, which reflect current management, 
differ depending on severity of disease and assessed interventions. Transition 
probabilities and utilities were taken from published literature. Drug costs 
(EGb761®€ 63/half-year, donepezil € 94/half-year) and costs of mild/moderately 
severe/severe dementia (€ 192/€ 318/€ 1,709 per half-year) were derived based on 
statement of KOLs and reimbursed lists. Costs and outcomes were discounted 
by 3%. Probability sensitivity analysis (PSA; 3,000 iteration) was performed with 
willingness-to-pay (WTP) threshold of 3 times GDP per capita in the Czech Republic 
(i.e. € 44,000). Results: EGb761® was dominant compared to no treatment in both 
mild AD and mild VaD while generating cost savings of € 560 and € 355 and gaining 
0.2150QALYs/0.1287LYGs and 0.1841QALYs/0.11439LYGs over a 10-year horizon. In 
comparison to active therapy in mild AD, EGb761® is slightly less efficient (loss 
of 0.0025QALYs/0.0001LYGs), but also cheaper (by € 35) than AChEI in a 10-year 
horizon. PSA showed that probability of EGb761®to be cost-effective varies from 
50% to 84% at the WTP threshold. ConClusions: EGb761® represents a cost-
saving intervention with more QALY gained, i.e. dominant therapy compared to 
no pharmacotherapy in treatment of mild dementia in 10 years. EGb761® shows 
very similar results (slightly cheaper and less efficient) in comparison to AchEI 
(e.g. donepezil) in the therapy of mild AD.
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objeCtives: The objective of this literature review was to explore the exist-
ing evidences regarding cost-effectiveness of interventions used to treat epi-
lepsy. Methods: A systematic literature review was performed using the PICO 
method: Population was patients suffering from epilepsy; Intervention and 
Comparators were any treatments, including non-pharmacological treatments, and 
Outcomes were ICERs. The literature search was performed with the NHS EED filters 
using MEDLINE, EMBASE and PubMed from January 2005 to May 5th, 2015. Results: 
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objeCtives: Self-injectable disease-modifying therapies (DMTs) are the first-line 
standard of care for relapsing-remitting multiple sclerosis (RRMS) in Scotland: 
Interferon beta (IFNβ )-1a (22mcg and 44mcg three times/week, and 30mcg once/
week), IFNβ -1b 250mcg every other day, and glatiramer acetate (GA) 20mg once/
day. Peginterferon beta-1a (PEG-IFN; 125mcg subcutaneous every two weeks) is a 
new DMT with less frequent dosing which may improve treatment adherence. The 
pivotal ADVANCE trial showed benefits of PEG-IFN versus placebo on relapses and 
disability progression, but its long-term clinical and economic consequences ver-
sus other DMTs are still unknown. This analysis assessed the cost-effectiveness of 
PEG-IFN versus self-injectable DMTs from the National Health System perspective 
in Scotland. Methods: A Markov cohort economic model, published and accepted 
by health technology assessment authorities, was adapted for this analysis. The 
model predicts disability progression (measured by the Expanded Disability Status 
Scale [EDSS]) and occurrence of relapses and other adverse events (AEs), and trans-
lates them into quality-adjusted life-years and costs. The natural history data were 
obtained from the placebo arm of the ADVANCE trial extrapolated with data from 
the London, Ontario database for EDSS transition probabilities and from a large 
population-based MS survey for relapse rates. A network meta-analysis was con-
ducted to estimate the comparative efficacy of each treatment versus placebo. Costs 
(in 2014 British Pounds) of drug acquisition, disease management, relapses, and 
AEs were from public databases and literature. Clinical and economic outcomes 
were projected over 30 years and discounted at 3.5% per year. Results: Over 30 
years, PEG-IFN yielded greater clinical benefits and cost savings compared with 
IFNβ -1a 22mcg IFNβ -1a 30mcg, and IFNβ -1b 250mcg. Compared with GA 20mg and 
IFNβ -1a 44mcg, the incremental cost-effectiveness ratios were £17,821 and £4,121, 
respectively. Deterministic and probabilistic sensitivity analyses confirmed that 
the results were robust. ConClusions: PEG-IFN is a cost-effective treatment for 
patients with RRMS in Scotland.
PND44
Cost-EffECtivENEss of first-liNE DisEAsE-moDifyiNG thErAPiEs (Dmts) 
for rElAPsiNG-rEmittiNG ms (rrms)
Soini EJ1, Joutseno J2, Sumelahti M3
1ESIOR Oy, Kuopio, Finland, 2Genzyme, a Sanofi company, Helsinki, Finland, 3School of Medicine, 
University of Tampere, Tampere, Finland
objeCtives: Teriflunomide 14 mg is the only first-line DMT with significant reduc-
tion in both relapses and 12-week disability progression in 2 pivotal clinical trials. 
Cost-effectiveness of teriflunomide 14 mg once daily orally vs other first-line DMTs 
for RRMS (oral dimethyl fumarate [DMF] 240 mg twice daily; subcutaneous glatiramer 
acetate (GA) 20 mg daily, interferon ([IFN] β -1a 44 µg 3× /week, and IFNβ -1b 250 µg 
every other day; intramuscular IFNβ -1a 30 µg once weekly) and best supportive care 
(BSC) were evaluated in the Finnish healthcare payer setting. Methods: The primary 
outcome was incremental cost-effectiveness ratio (ICER; € /quality-adjusted life-year 
[QALY] gained vs nondominated alternatives). Markov cohort modeling with a 20-year 
time horizon (3%/year discount rate) was employed. During each 1-year modeling 
cycle, patients could maintain their Expanded Disability Status Scale (EDSS) score or 
experience progression, develop secondary-progressive MS (SPMS), have EDSS pro-
gression in SPMS, or experience relapse with/without hospitalization or death. Patient 
characteristics, standardized mortality ratios, and an RRMS progression matrix were 
derived from a Finnish MS registry. Specific annual adverse event (AE) risks were 
included. A mixed-treatment comparison informed treatment effects. EQ-5D quality-
of-life estimates and Finnish direct costs were associated with EDSS scores, relapses, 
and AEs. Robustness of base case results was tested with probabilistic sensitivity 
analyses (PSAs). Results: Teriflunomide was less costly with higher QALYs vs GA and 
IFNs. DMF brought marginally more QALYs than teriflunomide (0.129 over 20 years); 
this difference was associated with higher costs. The ICER for DMF vs teriflunomide 
was 78,092, and teriflunomide had the lowest ICER of 17,326 vs BSC. In the PSAs, 
teriflunomide had over 50% cost-effectiveness probabilities, with willingness-to-pay 
values below € 94,000/QALY gained vs other first-line DMTs. ConClusions: The cost-
effectiveness of teriflunomide 14 mg once daily vs DMF twice daily and dominance 
over other first-line DMTs for RRMS were demonstrated in this Finnish study.
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objeCtives: Peginterferon beta-1a (PEG-IFN; 125mcg subcutaneous every 2 weeks) 
is a new disease-modifying therapy (DMT) for relapsing-remitting multiple scle-
rosis (RRMS) that may improve treatment adherence by reducing the frequency 
of administration. The pivotal ADVANCE trial showed benefits of PEG-IFN versus 
placebo on relapses and disability progression, but its long-term clinical and eco-
nomic consequences versus other DMTs are still unknown. This analysis assessed 
the cost-effectiveness of PEG-IFN versus other self-injectable DMTs (Interferon 
beta-1a 22mcg and 44mcg three times/week, and 30mcg once/week; interferon 
beta-1b 250mcg every other day; and glatiramer acetate 20mg once/day) from the 
Health Services Executive perspective in Ireland. Methods: An economic model, 
using a Markov cohort approach, published and accepted by health technology 
assessment authorities, was adapted for this analysis. The model predicts dis-
ability progression (measured by the Expanded Disability Status Scale [EDSS]) 
and occurrence of relapses and other adverse events (AEs), and translates them 
into quality-adjusted life-years (QALYs) and costs. Natural history data were 
obtained from the placebo arm of the ADVANCE trial extrapolated with data from 
the London, Ontario database for EDSS transition probabilities and from a large 
